DHR · DANAHER CORP /DE/

429 filings

DHR SEC Filings

DANAHER CORP /DE/ - 429 total filings

Filing record · 2016–202610-K1110-Q328-K138

Showing 1–50 of 429 filings

DANAHER CORP /DE/ 8-K Report, Executive Changes (Oct 13, 2026)

Danaher Corporation (DHR) announced significant changes to its Board of Directors via an 8-K filing on October 13, 2026. The Board's size was increased to thirteen members with the immediate appointment of two new directors: Daniel L. Comas and Robert M. Hershberg. Mr. Comas brings extensive financial and corporate development experience from his long tenure at Danaher, including serving as CFO. Dr. Hershberg adds deep scientific and executive leadership expertise from the biotechnology sector. Both will serve until the next annual shareholder meeting and will receive compensation consistent with the Company's non-employee director program, including prorated cash and equity awards. In addition to these appointments, the filing notes the upcoming retirement of director Alan G. Spoon, who will not seek re-election at the 2027 annual meeting, a decision not driven by any disagreements. Furthermore, Steven M. Rales and Mitchell P. Rales, the Company's co-founders and key board members, have waived their rights to significant restricted stock unit grants previously awarded to them. These board changes and director actions reflect ongoing governance and refreshment processes at Danaher.

Oct 13, 2026 8-K

DANAHER CORP /DE/ 8-K Report, Executive Changes (Aug 3, 2026)

Danaher Corporation (NYSE: DHR) announced on August 3, 2026 a CEO succession. Julie Sawyer Montgomery, a Danaher executive since 2017 who currently leads the Diagnostics platform as Executive Vice President, will become President and CEO effective October 1, 2026, and will join the Board and its Executive, Finance and Science & Technology Committees. Rainer M. Blair steps down as CEO and director on the same date, moving to a Senior Advisor role through December 31, 2026 and then a consultancy through March 31, 2027. The filing states there is no change to previously communicated third quarter and full-year 2026 guidance. Compensation for the new CEO is substantial. Her base salary rises to $1.5 million, with a 200% target annual cash incentive and a 2027 long-term incentive target of $13.2 million. She also receives a one-time $20 million stock option award (ten-year term, 50% vesting at years four and five), and her severance package includes 12 months of salary plus target bonus amounts. Chairman Steven Rales and Mitchell Rales, co-founders, also received special option and RSU grants (1,000,000 options and 500,000 RSUs each) under a Long-Term Growth Program. The company expects to exclude the stock-based compensation expense for this program from Adjusted Diluted EPS, which is a notable point for investors reviewing non-GAAP earnings. For investors, the key items are continuity of the Diagnostics-led strategy, an orderly transition with Blair remaining available through the advisory period, and the scale of equity incentives tied to long-term growth. Investors should watch execution on the pending StatLab acquisition and the Masimo integration, as well as how the Adjusted EPS exclusion is presented going forward.

Aug 3, 2026 10-Q

DANAHER CORP /DE/ Quarterly Report for Q2 Ended Jun 26, 2026

Danaher's second quarter 2026 results were shaped by the closing of its roughly $9.8 billion cash acquisition of Masimo on June 10, 2026, which is now part of the Diagnostics segment. Reported sales rose 5.5% year over year to $6.27 billion, with core sales up 3.0% (4.5% excluding respiratory testing). Diluted EPS was $1.23 versus $0.77 a year earlier, but the comparison is flattered by a $432 million trade name impairment in Q2 2025. Operating margin expanded to 18.0% from 12.8%, though Q2 2026 absorbed about 175 basis points of Masimo-related charges (inventory step-up, transaction costs, and change-in-control and share-based payments). Gross margin contracted to 57.6% from 59.3%, reflecting product mix, the inventory fair value adjustment, and acquired businesses. The balance sheet changed materially. Total assets rose to $92.4 billion from $83.5 billion, goodwill increased to $47.4 billion, and intangibles to $21.4 billion. Total debt reached about $26.6 billion, up from $18.4 billion, funded by commercial paper and roughly $6.5 billion of new long-term notes in euros and Swiss francs. Cash fell to $4.3 billion. Operating cash flow was $2.9 billion for the first half, up 8%, while the company continued share repurchases ($903 million in Q2) and raised dividends. Management expects a full-year 2026 effective tax rate of about 17%, and disclosed a new core sales measure excluding respiratory testing, along with plans to exclude tariff refunds from core sales beginning in Q3. Key risks for investors include the leverage increase and resulting interest expense, the integration of Masimo including its ongoing litigation (Apple, DOJ investigation, Kiani disputes, and Willow arbitration), a securities class action settlement awaiting final approval on September 3, 2026, uncertainty around IEEPA tariff refunds, and Middle East conflict effects on logistics and energy costs. China pricing pressure in Diagnostics and a weaker respiratory season also weighed on segment core sales.

Jul 21, 2026 8-K

DANAHER CORP /DE/ 8-K Report, Financial Results (Jul 21, 2026)

Danaher reported second quarter 2026 results for the period ended June 26, 2026, with GAAP net earnings of $870 million, or $1.23 per diluted share, up 60% year-over-year, and revenue up 5.5% to $6.3 billion. The GAAP improvement is flattered by a sharp drop in SG&A expense and by a prior-year impairment charge of $432 million on a trade name, so the cleaner comparison is the non-GAAP measure. Adjusted diluted EPS rose 8.0% to $1.94, and non-GAAP core revenue grew 3.0%, or 4.5% excluding respiratory testing. Operating cash flow was $1.5 billion and free cash flow was $1.3 billion. Interest expense rose and interest income increased sharply, reflecting the debt raised to finance the Masimo acquisition, which Danaher completed earlier than anticipated. Management raised full-year 2026 adjusted diluted EPS guidance to $8.45 to $8.60 from $8.35 to $8.55, while narrowing the organic growth outlook to 3.0% to 4.0% core revenue growth. The third-quarter core growth outlook is 2.0% to 3.0%. Bioprocessing was a bright spot in orders, growing in the mid-teens, but reported bioprocessing revenue was affected by customer project timing. Management expects to exit 2026 at a mid-single-digit core growth rate. Danaher also disclosed a pending acquisition of StatLab (about $250 million in 2025 revenue, more than 85% recurring) by Leica Biosystems, expected to close by year-end 2026 and to be accretive in its first full year. For investors, the key questions are the durability of the core growth recovery, the pace of deleveraging after the Masimo financing, and how much of the EPS raise reflects operations versus the lower share count and tax and interest items. Respiratory testing revenue, which is highly sensitive to flu severity, continues to distort reported Diagnostics growth, and the company has added a new non-GAAP measure to address this. Management also plans to exclude tariff refunds from core sales beginning in the third quarter, a change that could make future growth comparisons harder to read.

Jul 21, 2026 8-K

DANAHER CORP /DE/ 8-K Report, Financial Obligation (Jun 3, 2026)

On June 3, 2026, Danaher Corporation and its wholly owned subsidiary DH Masi Finance Inc. closed a private placement of seven series of Swiss franc senior notes under a Note Purchase Agreement with institutional accredited investors. The notes total approximately CHF 2.38 billion (about CHF 2,382.9 million) across maturities from 2031 to 2056. The Issuer is DH Masi Finance Inc., and Danaher fully and unconditionally guarantees the notes. The notes are unsecured and were sold in an offering exempt from Securities Act registration. The coupons range from 1.65% for the 5-year Series A notes to 2.50% for the 30-year Series G notes, with a principal-weighted average coupon of roughly 2.3%. Because the notes are denominated in Swiss francs, the low coupons reflect Swiss rates rather than U.S. dollar rates. Interest is payable semi-annually beginning December 3, 2026. The filing states that net proceeds will fund general corporate purposes, including working capital, acquisitions, and share repurchases. Investors should note that this transaction adds to Danaher's long-term debt load, though the filing does not disclose the USD equivalent, hedging arrangements, or pro forma leverage impact. The filing describes the covenants and events of default as customary and broadly consistent with Danaher's existing debt, including its credit facilities. It does not indicate any material change to the company's financial condition. Overall, the filing reflects a low-cost, long-dated financing that extends Danaher's maturity profile and diversifies its funding sources into the Swiss franc market.

Jun 3, 2026 8-K

DANAHER CORP /DE/ 8-K Report, Executive Changes (May 7, 2026)

Danaher Corporation (DHR) filed an 8-K on May 7, 2026, detailing outcomes from its Annual Meeting of Shareholders held on May 5, 2026. The most significant event for investors is the shareholder approval of the Amended and Restated Danaher Corporation Omnibus Incentive Plan. This plan was updated to increase the share reserve by 20 million shares of Common Stock and extend its term to May 5, 2036, indicating continued focus on executive and employee compensation through equity incentives. Additionally, the filing confirms the election of all eleven director nominees and the ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. Shareholders also approved, on an advisory basis, the compensation of the company's named executive officers. These approvals reflect shareholder confidence in the company's governance and executive compensation strategies.

May 7, 2026 8-K

DANAHER CORP /DE/ 8-K Report, Material Agreement (Apr 29, 2026)

Danaher Corporation (DHR) has filed an 8-K detailing the issuance of €2.98 billion (approximately) in senior notes. This offering includes both floating-rate notes maturing in 2028 and fixed-rate notes with maturities in 2030, 2034, and 2038, carrying interest rates of 3.250%, 3.625%, and 4.000% respectively. The primary stated use of these proceeds is to fund a portion of the cash consideration and associated costs for the proposed acquisition of Masimo Corporation. Danaher also retains the flexibility to use a portion of the proceeds for general corporate purposes, including debt refinancing and working capital. This debt issuance provides significant capital to support Danaher's strategic growth initiatives, particularly the pending Masimo acquisition. The notes are unsecured senior indebtedness, ranking equally with existing unsecured senior debt. Investors should note the early redemption provisions, including a potential "Par Call" option for fixed-rate notes and a special mandatory redemption if the Masimo Acquisition is not consummated, which would trigger a redemption at 101% of the principal amount. Additionally, a change of control triggering event would allow noteholders to demand repurchase at 101%.

Apr 29, 2026 8-K

DANAHER CORP /DE/ 8-K Report, Financial Results (Apr 21, 2026)

Danaher reported first quarter 2026 results (quarter ended March 27, 2026) with GAAP net earnings of $1.0 billion, or $1.45 per diluted share, up from $1.32 a year earlier. Non-GAAP adjusted diluted EPS rose 9.5% to $2.06. Reported sales increased 3.5% to $5.95 billion, but this was driven largely by favorable currency (roughly +3.0 points); non-GAAP core sales grew only 0.5%. Biotechnology was the standout, with core sales up 7.0%, while Diagnostics declined 4.0% core, reflecting a lighter-than-typical respiratory season at Cepheid. Operating cash flow was $1.3 billion and free cash flow was $1.1 billion. Management raised the low end of full-year 2026 adjusted EPS guidance, moving the range to $8.35 to $8.55 from $8.35 to $8.50, and kept the 3% to 6% core revenue growth outlook. Second-quarter core growth is guided to the low-single-digit range. The company also disclosed its intention to acquire Masimo Corporation, a pulse oximetry and patient monitoring provider, subject to customary closing conditions including regulatory approval. Investors should note that the filing does not quantify the purchase price or financing, and the guidance excludes incremental interest expense tied to the deal, so the transaction could change the outlook materially once it is finalized. Quality of the beat is mixed. EPS growth benefited from lower share count and operating leverage, while core top-line growth remained modest and the Diagnostics segment is under pressure. The main near-term watch items are the Masimo financing and integration, Cepheid respiratory revenue (guided to about $1.6 to $1.7 billion for 2026), and whether Bioprocessing momentum continues.

Apr 21, 2026 10-Q

DANAHER CORP /DE/ Quarterly Report for Q1 Ended Mar 27, 2026

Danaher's first quarter 2026 (ended March 27, 2026) showed modest top-line growth with GAAP sales up 3.5% to $5.95 billion, but core sales grew only 0.5% after excluding a 3.0% currency tailwind. Net earnings rose 8% to $1.03 billion, and diluted EPS increased to $1.45 from $1.32, helped by a 40 basis point improvement in operating margin to 22.6%, lower net interest expense, and a share count that fell about 1.3% year over year. Growth was uneven across segments: Biotechnology core sales rose 7.0% led by bioprocessing consumables, Life Sciences rose 0.5%, and Diagnostics declined 4.0% on weaker respiratory testing and China volume-based procurement pricing. Balance sheet and cash flow shifted notably. Cash rose to $5.7 billion from $4.6 billion, largely funded by about $1.7 billion of net commercial paper issuance, while total debt was roughly flat at $18.5 billion. Operating cash flow was $1.32 billion, up 2%. Management disclosed a pending $9.9 billion cash acquisition of Masimo Corporation, to be placed in the Diagnostics segment and financed with cash on hand and new debt. Subsequent to quarter end, Danaher entered a $5.0 billion 364-day credit facility to backstop commercial paper used toward that purchase, which signals significant incremental leverage ahead. Investors should weigh the strong earnings and cash generation against the thin underlying organic growth, the Diagnostics weakness, and the leverage and integration risk from Masimo. The filing also flags tariff uncertainty following the Supreme Court IEEPA ruling, Middle East conflict cost pressures, and a pending securities class action settlement subject to court approval.

Apr 21, 2026 8-K

DANAHER CORP /DE/ 8-K Report, Material Agreement (Apr 17, 2026)

Danaher Corporation (DHR) has entered into a new $5.0 billion 364-day revolving credit facility, maturing on April 15, 2027. This facility, with Bank of America, N.A. as Administrative Agent and a syndicate of lenders, is designed to provide liquidity support for Danaher's U.S. dollar-denominated commercial paper program and for general corporate purposes. The agreement offers flexibility, including the option to convert outstanding loans into term loans one year after the scheduled termination date, subject to certain conditions and fees. This strategic move bolsters Danaher's financial flexibility and operational capacity.

Apr 17, 2026 10-K

DANAHER CORP /DE/ Annual Report, Year Ended Dec 31, 2025

Danaher Corporation (DHR) reported solid performance for the fiscal year ending December 31, 2025, with total sales increasing by 3.0% to $24.57 billion. The company's core sales, excluding currency impacts and acquisitions, grew by 2.0%, primarily driven by strength in the Biotechnology and Diagnostics segments, though the Life Sciences segment saw a slight decline. Net earnings from continuing operations were $3.60 billion, or $5.03 per diluted share, a decrease from the prior year primarily due to intangible asset impairments. Despite these impairments, Danaher maintained robust operating profit margins of 19.1%. The company's strategic focus on strengthening competitive advantages through the Danaher Business System (DBS), enhancing its portfolio via strategic capital allocation, and attracting top talent continues to guide its operations. Danaher also announced a significant pending acquisition of Masimo Corporation for approximately $9.9 billion, further underscoring its commitment to strategic growth in attractive science and technology markets.

Feb 24, 2026 8-K

DANAHER CORP /DE/ 8-K Report, Corporate Update (Feb 17, 2026)

Danaher Corporation (NYSE: DHR) has agreed to acquire Masimo Corporation (NASDAQ: MASI), a provider of pulse oximetry and patient monitoring solutions primarily used in acute care settings, for $180.00 per share in cash. The transaction carries an implied total enterprise value of approximately $9.9 billion, including assumed indebtedness and net of acquired cash. Danaher cites a transaction multiple of roughly 18x estimated 2027 EBITDA, or about 15x including the full benefit of expected annual synergies. The Merger Agreement is dated February 16, 2026, and was announced via press release on February 17, 2026. Masimo will become a wholly owned subsidiary of Danaher and a standalone operating company within its Diagnostics segment. For investors, the deal's financial profile centers on accretion and synergies. Danaher expects Masimo to be accretive to adjusted diluted EPS by $0.15 to $0.20 in the first full year and approximately $0.70 in the fifth full year, and projects Masimo's 2027 EBITDA at more than $530 million under Danaher ownership. Management targets more than $125 million of annual cost synergies and more than $50 million of annual revenue synergies by the fifth full year after closing. Danaher plans to fund the purchase with cash on hand and debt financing, which will add leverage to its balance sheet. The filing does not disclose the premium paid or the size of any termination fee. Closing is expected in the second half of 2026 and is subject to the expiration of the HSR waiting period, certain non-U.S. antitrust and foreign direct investment approvals, and approval by Masimo stockholders. Key risks include regulatory review, the possibility of competing bids, stockholder litigation, and the failure to realize expected synergies. Note that the non-GAAP figures cited (adjusted EPS, core revenue growth, EBITDA) are not reconciled to GAAP in the release.

Feb 17, 2026 8-K

DANAHER CORP /DE/ 8-K Report, Executive Changes (Feb 10, 2026)

Danaher Corporation (DHR) announced a change to its Board of Directors with the retirement of Jessica L. Mega, effective February 5, 2026. Dr. Mega's departure is attributed to increasing commitments from her other professional endeavors and is not a reflection of any disagreements with the company's operations, policies, or practices. This event, while noted, does not appear to signal any material operational or strategic shifts for Danaher at this time, but investors should monitor board composition for any long-term implications. The filing also includes the standard XBRL interactive data file. Investors should consider this an administrative update concerning board membership rather than a primary driver of near-term stock performance. The company continues its focus on its core business segments, and the absence of Dr. Mega from the board is not expected to impact the company's strategic direction or financial performance.

Feb 10, 2026 8-K

DANAHER CORP /DE/ 8-K Report, Financial Results (Jan 28, 2026)

Danaher reported fourth quarter and full year 2025 results on January 28, 2026, with all figures reflecting continuing operations. Fourth quarter revenue rose 4.5% year-over-year to $6.8 billion, but core (organic, ex-FX and acquisitions) revenue grew a more modest 2.5%, with currency contributing a 2.5-point tailwind to reported growth. GAAP diluted EPS was $1.66 versus $1.49 a year earlier, while non-GAAP adjusted diluted EPS grew 4.0% to $2.23. For full year 2025, revenue reached $24.6 billion (up 3.0%, core up 2.0%), GAAP diluted EPS was $5.03 (down from $5.29, largely due to $432 million of trade-name impairments in Life Sciences and other impairments totaling $562 million in cash-flow terms), and adjusted EPS rose 4.5% to $7.80. Cash generation remained strong, with full year operating cash flow of $6.4 billion and free cash flow of $5.3 billion, roughly flat with 2024. Capital allocation shifted toward the balance sheet and dividends: cash and equivalents rose to $4.6 billion from $2.1 billion, long-term debt increased to $18.4 billion from $15.5 billion after $1.6 billion of new borrowings, and share repurchases fell to $3.1 billion from $6.0 billion. Dividends paid rose to $878 million. Goodwill grew to $43.2 billion, reflecting acquisition activity during the period. For 2026, management guides to core revenue growth of 3% to 6% and adjusted diluted EPS of $8.35 to $8.50, implying roughly 7% to 9% adjusted EPS growth. First quarter core growth is guided to low-single digits. Segment outlooks are mixed: Biotechnology is expected to grow about 6% for the year, Diagnostics low-single digits, and Life Sciences flat. CEO Rainer Blair expressed confidence in gradual end-market improvement, though guidance is subject to tariff, currency, and macro risks.

Jan 28, 2026 8-K

DANAHER CORP /DE/ 8-K Report, Financial Results (Jan 12, 2026)

Danaher Corporation (NYSE: DHR) furnished an 8-K on January 12, 2026, ahead of a CEO webcast at the J.P. Morgan Healthcare Conference on January 13, 2026, providing preliminary estimates for Q4 and full-year 2025 results. The filing contains no new financial statements or formal guidance changes; it is a preliminary update that points to a solid close to the year. Management estimates Q4 2025 total revenue growth in the mid-single-digit percent range year-over-year, with non-GAAP core revenue growth at the high end of the previously guided low-single-digit range. Core growth was partly offset by roughly a low-single-digit currency headwind, while acquisitions/divestitures added slightly. For full-year 2025, non-GAAP adjusted diluted EPS is expected to land toward the high end of the previously guided $7.70 to $7.80 range. Management highlighted strength in Bioprocessing (consumables up high-single digits, equipment up mid-single digits), better-than-expected Life Sciences and Diagnostics results, and mid-single-digit growth at SCIEX. The slides also introduce initial 2026 expectations of 3% to 6% core revenue growth, with adjusted operating profit margin expansion of more than 100 basis points and adjusted EPS growth in the high-single digits. For investors, the key takeaways are the upbeat tone on Q4 execution and the initial 2026 framework, which signals a gradual recovery toward long-term high-single-digit core growth. Investors should note that these are estimates ahead of the full earnings release, which is scheduled for January 28, 2026, and that the company's net debt to adjusted EBITDA was about 2.5x as of September 2025, leaving capacity for acquisitions.

Jan 12, 2026 8-K

DANAHER CORP /DE/ 8-K Report, Executive Changes (Nov 6, 2025)

Danaher Corporation (DHR) has filed a Current Report (8-K) primarily detailing a change in its Board of Directors. John T. Schwieters has informed the Board of his decision not to seek reelection at the upcoming 2026 annual meeting of shareholders, leading to his retirement from the Board at that time. Importantly, this decision is not attributed to any disagreements with the company regarding its operations, policies, or practices, which suggests a smooth transition and continued stable governance. As a consequence of Mr. Schwieters' retirement, the size of the Danaher Board will be reduced from thirteen to twelve members following his departure. This structural adjustment is a notable point for investors to consider regarding board composition and governance. The filing also includes the standard interactive data file exhibit.

Nov 6, 2025 8-K

DANAHER CORP /DE/ 8-K Report, Financial Results (Oct 21, 2025)

Danaher Corporation (NYSE: DHR) reported third quarter 2025 results for the quarter ended September 26, 2025, with sales up 4.5% year-over-year to $6.053 billion and non-GAAP core sales up 3.0%. GAAP net earnings were $908 million, or $1.27 per diluted share (up from $1.12), while non-GAAP adjusted diluted EPS was $1.89, up from $1.71 a year earlier. Management attributed the beat versus its own expectations to DBS-driven execution (Danaher Business System), continued momentum in bioprocessing, and better-than-anticipated respiratory revenue at Cepheid. Operating cash flow was $1.66 billion and free cash flow was $1.37 billion, up from $1.23 billion. The quarter was not without GAAP pressure. Operating profit rose to $1.154 billion from $958 million, but the year-over-year comparison is distorted by a large prior-year gain in other income and by impairments; nine-month GAAP diluted EPS fell to $3.37 from $3.80, largely due to a $432 million impairment of a Life Sciences trade name and other impairments totaling roughly $0.76 per share in the period. Amortization of acquisition-related intangibles ($0.61 per share in the quarter) remains a significant gap between GAAP and non-GAAP earnings. Biotechnology was the standout segment, with core growth of 6.5%, while Life Sciences core sales declined 1.0% and Diagnostics grew 3.5%. Currency was a 1.5% headwind to quarterly sales. Looking ahead, Danaher maintained its full-year 2025 adjusted diluted EPS guidance of $7.70 to $7.80 and expects low-single-digit core revenue growth for the year, with fourth-quarter Biotechnology growth of roughly 5%, flat Diagnostics, and a decline in Life Sciences. Nine-month adjusted EPS of $5.57 implies a fourth quarter in the range of roughly $2.13 to $2.23, so the guidance was held rather than raised. The release also includes forward-looking assumptions of roughly 2.5% currency tailwind to Q4 sales, a ~17% effective tax rate, and ~$50 million of net interest expense. Risks flagged include tariffs, AI-related uncertainties, and the impact of debt on liquidity.

Oct 21, 2025 10-Q

DANAHER CORP /DE/ Quarterly Report for Q3 Ended Sep 26, 2025

Danaher's Q3 2025 10-Q shows steady top-line momentum with third-quarter sales up 4.5% to $6.05 billion and core sales up 3.0%, led by Biotechnology (+6.5% core) and Diagnostics (+3.5% core), while Life Sciences declined about 1% in core sales. Diluted EPS rose to $1.27 from $1.12 in the prior-year quarter, and operating margin expanded to 19.1% from 16.5%, though the comparison is flattered by a $222 million impairment in Q3 2024. For the nine months, net earnings fell to $2.42 billion from $2.81 billion and diluted EPS to $3.37 from $3.80, driven mainly by $548 million of 2025 impairments (including a $432 million genomics trade name write-down in Life Sciences) and investment losses, partly offset by lower amortization and interest costs. Cash generation remained solid but softer: operating cash flow was $4.3 billion, down 8% year over year, and capital expenditures were $785 million. Danaher returned substantial capital to shareholders, repurchasing about $3.1 billion of stock in the nine months and paying $652 million in dividends, while also reducing treasury cash and cash equivalents to $1.5 billion. Total debt rose to about $16.9 billion, and management subsequently issued CHF 1.25 billion (about $1.6 billion) of Swiss franc bonds on October 10, 2025, which increases debt but adds liquidity for general corporate purposes including buybacks. Management flagged headwinds that investors should weigh: a cautious bioprocessing equipment environment, weaker academic and government funding, China volume-based procurement pressure in Diagnostics, several hundred million dollars of incremental 2025 tariff costs (largely offset so far), a U.S. government shutdown beginning in October 2025, and ongoing securities litigation (Hawkins Action) where the outcome cannot be estimated. The effective tax rate outlook for the remainder of 2025 is about 17%.

Oct 21, 2025 8-K

DANAHER CORP /DE/ 8-K Report, Bylaw Amendment (Sep 10, 2025)

Danaher Corporation (DHR) filed an 8-K on September 9, 2025, announcing two significant updates for its shareholders. First, the company's Board of Directors amended and restated the corporate By-laws, primarily focusing on revising the procedural and disclosure requirements for shareholders wishing to propose business or nominate directors at meetings. These changes are designed to streamline the process and ensure timely and adequate information sharing. Second, and more materially for investors, Danaher's Board approved a substantial new share repurchase program. This program authorizes the repurchase of up to 35 million shares of common stock, which can be executed through various methods including open market purchases and Rule 10b5-1 trading plans. This significant buyback authorization, which has no expiration date, signals management's confidence in the company's valuation and commitment to returning capital to shareholders.

Sep 10, 2025 8-K

DANAHER CORP /DE/ 8-K Report, Executive Changes (Jul 31, 2025)

Danaher Corporation (DHR) has filed an 8-K report disclosing a significant leadership transition within its legal department. Brian W. Ellis, Senior Vice President and General Counsel, has announced his intention to step down from his General Counsel role effective August 25, 2025. While relinquishing his primary legal leadership responsibilities, Mr. Ellis will remain with the company in an executive officer capacity as Senior Vice President, supporting the company until his planned retirement on February 28, 2026. This announcement marks a key change in Danaher's executive team. Investors should note that Mr. Ellis's continued involvement in a Senior Vice President role, albeit with a different focus, indicates a phased transition rather than an immediate departure. The company has not yet announced a successor for the General Counsel position, which will be a point of interest for stakeholders monitoring leadership continuity and strategic direction within Danaher's legal and executive functions.

Jul 31, 2025 8-K

DANAHER CORP /DE/ 8-K Report, Executive Changes (Jul 24, 2025)

Danaher Corporation (NYSE: DHR) announced in an 8-K filed July 24, 2025 that CFO Matthew McGrew will relinquish the CFO role effective February 28, 2026, remaining with the company as an Executive Vice President as he begins a gradual transition to retirement after more than 20 years at Danaher. Matthew Gugino, currently Vice President of Corporate FP&A and Group CFO of the Life Sciences Innovations group, will succeed him as EVP and Chief Financial Officer on that date. Gugino, 43, has been with Danaher since 2013 and previously led Investor Relations from 2014 to 2022, giving him deep familiarity with both the financial reporting and investor communication functions. The filing discloses a meaningful compensation step-up for Gugino tied to the promotion. His base salary rises to $700,000 immediately (July 21, 2025) and to $825,000 on February 28, 2026, with his target bonus moving to 90% for the remainder of 2025 and 115% from 2026. His equity grants increase to a $1.75 million target award in November 2025 and a $4.2 million target award for 2026, split between stock options and performance or time-vesting RSUs. McGrew's 2026 compensation is set at a $700,000 base salary, a 125% target bonus, and a $2.5 million equity target, reflecting his transition to a non-CFO executive role. Gugino also signed a non-competition and proprietary interests agreement and receives added perquisites such as limited aircraft use and financial planning reimbursement. For investors, the announcement is primarily a planned, orderly succession rather than a signal of operational distress, since McGrew is staying on through the transition and the incoming CFO is an internal candidate with long institutional knowledge. The main points to monitor are continuity in capital allocation, M&A integration, and guidance credibility during the handover, as well as whether the more aggressive incentive structure for Gugino drives execution against Danaher's growth and margin targets.

Jul 24, 2025 8-K

DANAHER CORP /DE/ 8-K Report, Financial Results (Jul 22, 2025)

Danaher reported second-quarter 2025 results for the quarter ended June 27, 2025, with revenue up 3.5% year-over-year to $5.9 billion, but GAAP profitability fell sharply. Net earnings were $555 million, or $0.77 per diluted share, versus $907 million, or $1.22, a year earlier. The decline is driven by a $432 million pretax impairment of a Life Sciences trade name, along with higher SG&A expenses ($2.36 billion vs. $1.87 billion) and much lower interest income ($8 million vs. $39 million). Excluding these and other items, adjusted diluted EPS rose to $1.80 from $1.72, about 5%, and management said results exceeded its expectations. Underlying growth was more modest than headline sales growth suggests. Non-GAAP core revenue grew 1.5%, with currency adding roughly 2 points. Biotechnology was the standout, with core sales up 6.0%, while Life Sciences declined 2.5% on a core basis and Diagnostics grew 2.0%. Operating cash flow was $1.3 billion and free cash flow was $1.1 billion, both broadly flat with the prior year. Six-month GAAP net earnings were $1.51 billion versus $2.00 billion, reflecting the same charges. Looking ahead, management expects third-quarter core revenue growth in the low-single digits and maintained full-year core growth of about 3%. It raised full-year adjusted diluted EPS guidance to $7.70–$7.80 from $7.60–$7.75. Management says the macro environment remains fluid, and the filing lists tariffs, currency, and Life Sciences trade name impairment risk among the factors to watch.

Jul 22, 2025 10-Q

DANAHER CORP /DE/ Quarterly Report for Q2 Ended Jun 27, 2025

Danaher's second-quarter 2025 results were dominated by a non-cash impairment. Revenue rose 3.5% year over year to $5.94 billion, with core sales up 1.5% and currency adding 2.0%. Diagnostics and Biotechnology grew core sales, while Life Sciences declined. Net earnings fell 39% to $555 million, or $0.77 per diluted share, versus $1.22 a year earlier. The drop reflects a $432 million pretax ($328 million after-tax) impairment of a genomics consumables trade name in Life Sciences, which was SG&A-classified and drove the operating margin down to 12.8% from 20.3%. Excluding the charge, the underlying picture is steadier than the headline suggests, though SG&A and gross margin pressure from tariffs and currency are worth monitoring. Cash generation and the balance sheet remained solid. Operating cash flow for the first half was $2.6 billion, down 16%, largely reflecting lower earnings and working-capital timing. Management repurchased about $1.1 billion of stock in the first half, and cash rose to $3.0 billion. Total debt increased to $17.4 billion, and the company is shifting part of its commercial paper into long-term classification. Management expects enacted tariffs to add several hundred million dollars of incremental cost for 2025, which it expects to largely offset, while the effective tax rate for the remainder of 2025 is guided to about 17%. The filing also flags forward-looking risks: additional tariffs that have been delayed or threatened could be material, academic and government demand is expected to stay weak, and China volume-based procurement continues to weigh on Diagnostics. Goodwill headroom in the reorganized Life Sciences reporting units is narrower than before, with a hypothetical 10% fair-value decline still leaving cushion, so further impairments are possible if genomics demand does not recover.

Jul 22, 2025 8-K

DANAHER CORP /DE/ 8-K Report, Shareholder Vote Results (May 8, 2025)

Danaher Corporation (DHR) filed an 8-K on May 7, 2025, detailing the results of its annual shareholder meeting held on May 6, 2025. The primary focus of the filing is the voting outcomes on key corporate governance and operational matters. All thirteen director nominees were overwhelmingly elected, indicating strong shareholder confidence in the current board leadership. Shareholders also ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, a standard procedure that reinforces oversight of financial reporting. Furthermore, the advisory vote on the compensation of the Company's named executive officers received majority approval. While the specific compensation details are not within this 8-K, the positive vote suggests shareholder satisfaction with the executive compensation structure. The filing also includes the standard Cover Page Interactive Data File in XBRL format, facilitating easier access to financial data for investors and analysts.

May 8, 2025 8-K

DANAHER CORP /DE/ 8-K Report, Financial Results (Apr 22, 2025)

Danaher reported first-quarter 2025 results for the period ended March 28, 2025, with GAAP sales of $5.74 billion, down 1.0% year over year. Non-GAAP core sales were flat, which management described as ahead of its expectations. GAAP net earnings were $954 million, or $1.32 per diluted share, versus $1.45 a year earlier. Adjusted diluted EPS was $1.88, down from $1.92. The decline in GAAP earnings was driven by higher amortization of acquisition-related intangibles, a larger fair value loss on investments, and lower interest income. Operating cash flow was $1.30 billion and free cash flow was $1.06 billion (the press release rounds these to $1.3 billion and $1.1 billion). Segment performance was uneven. Biotechnology was the clear standout, with core sales up 7%, which management attributed to continued bioprocessing momentum. Life Sciences core sales fell 4%, and Diagnostics core sales declined 1.5%, though molecular diagnostics respiratory demand was better than expected. Management said the macro backdrop has become more dynamic, citing tariffs and related trade actions as a forward-looking risk. For guidance, management expects second-quarter core revenue to grow at a low-single-digit rate year over year. Full-year 2025 core revenue growth of approximately 3% is unchanged. Danaher is initiating full-year adjusted diluted EPS guidance of $7.60 to $7.75. The company does not provide GAAP EPS guidance because of the difficulty of forecasting investment gains and losses and discrete tax items.

Apr 22, 2025 10-Q

DANAHER CORP /DE/ Quarterly Report for Q1 Ended Mar 28, 2025

Danaher's first quarter 2025 results (three months ended March 28, 2025) show a modest top-line softness with pressure on profitability and earnings. Sales were $5,741 million, down 1.0% year over year from $5,796 million. Core sales (excluding acquisitions and currency) were flat: Biotechnology grew 7.0%, while Life Sciences core sales fell 4.0% and Diagnostics fell 1.5%. Currency reduced reported sales by 1.5%, and acquisitions added 0.5%. Operating profit fell to $1,274 million from $1,312 million, with margin declining 40 basis points to 22.2%. Net earnings dropped 12% to $954 million, and diluted EPS fell to $1.32 from $1.45. The decline reflected higher SG&A (32.4% of sales versus 31.2%, driven by productivity-program costs), a $15 million facility impairment, a $90 million investment loss, and higher net interest expense. Cash generation and capital allocation were notable. Operating cash flow fell 25% to $1.3 billion, mainly due to lower earnings and working-capital timing. Danaher repurchased about $1.1 billion of stock (roughly 4.5 million shares at an average of about $239), leaving about 12 million shares authorized. Cash ended the quarter at $2.0 billion, and long-term debt rose to $16.0 billion. Comprehensive income of $2.56 billion was driven mainly by a $1.4 billion foreign currency translation gain, which is non-cash and reflects the weaker U.S. dollar. Balance sheet goodwill rose to $41.7 billion, largely from currency translation. Management flagged meaningful forward risk from new U.S. tariffs and retaliatory measures. The company expects several hundred million dollars of incremental tariff costs in 2025, which it intends to largely offset through sourcing changes, surcharges, and productivity actions. It expects end-market demand for the rest of 2025 to be roughly consistent with Q1, and projects a full-year-remaining effective tax rate of about 17%.

Apr 22, 2025 10-K

DANAHER CORP /DE/ Annual Report, Year Ended Dec 31, 2024

Danaher Corporation (DHR) reported flat total sales for the fiscal year ended December 30, 2024, with a 1.5% decrease in core sales. This performance was influenced by a 2.0% boost from acquisitions, which partially offset declines in the Biotechnology and Life Sciences segments, while the Diagnostics segment showed growth. Net earnings from continuing operations declined to $3.9 billion from $4.2 billion in the prior year, impacted by intangible asset impairments and increased operating expenses. The company's strategic priorities remain focused on strengthening competitive advantage through the Danaher Business System (DBS), enhancing its portfolio via strategic capital allocation, and attracting top talent. Looking ahead, Danaher has initiated a cost savings program expected to generate at least $150 million in annual pre-tax savings starting in Q1 2025. The company also continues to manage its capital structure, evidenced by significant share repurchases totaling $6.0 billion in 2024. Despite a challenging macro-economic environment, including global economic uncertainty and inflationary pressures, Danaher's diversified business model across life sciences, diagnostics, and biotechnology sectors provides a degree of resilience.

Feb 20, 2025 8-K

DANAHER CORP /DE/ 8-K Report, Executive Changes (Feb 20, 2025)

Danaher Corporation (DHR) filed an 8-K report on February 20, 2025, announcing two key updates: the appointment of a new independent director and an amendment to its 2007 Omnibus Incentive Plan. Charles W. Lamanna has joined the Board of Directors and will serve on the Science & Technology Committee. His appointment is considered independent and he will receive standard compensation for non-employee directors, including equity awards. The second significant development involves an amendment to the Company's 2007 Omnibus Incentive Plan. This amendment enhances benefits for participants whose employment or service terminates due to death or disability. Specifically, unvested stock options and restricted stock units will now fully vest, and performance stock units (PSUs) will vest at the target level if the termination event occurs before the performance period concludes. These changes aim to provide greater financial security to key personnel and their estates in the event of unforeseen circumstances.

Feb 20, 2025 8-K

DANAHER CORP /DE/ 8-K Report, Financial Results (Jan 29, 2025)

Danaher reported fourth-quarter and full-year 2024 results on January 29, 2025, with all figures reflecting continuing operations. For Q4 2024, revenue rose 2.0% year-over-year to $6.5 billion, with non-GAAP core revenue up 1.0%. GAAP diluted EPS was $1.49 and non-GAAP adjusted diluted EPS was $2.14, versus $2.09 a year earlier. Operating cash flow was $2.0 billion and free cash flow was $1.5 billion, up roughly 29.5% year-over-year. Management highlighted better-than-anticipated core revenue across all three segments and operating margin expansion. For full-year 2024, sales were flat at $23.9 billion, but non-GAAP core revenue declined 1.5%. GAAP diluted EPS was $5.29 and adjusted diluted EPS was $7.48, down from $7.58. Operating profit fell to $4.9 billion from $5.2 billion, though the operating margin was 20.4% versus 21.8%. Free cash flow was $5.3 billion, up about 3.5%. The balance sheet shows cash falling to $2.1 billion from $5.9 billion, mainly because of $6.0 billion in share repurchases, and total debt declining to about $16.0 billion. Management pointed to a more focused life sciences and diagnostics portfolio as the basis for higher long-term growth and margins. Guidance is mixed. Management expects first-quarter 2025 core revenue to decline low-single digits year-over-year, and full-year 2025 core revenue to grow about 3%. Investors should weigh the strong cash generation and buybacks against a soft start to 2025, the Biotechnology and Life Sciences core declines in 2024, and the continued goodwill and intangible asset amortization burden.

Jan 29, 2025 8-K

DANAHER CORP /DE/ 8-K Report, Financial Results (Jan 13, 2025)

Danaher Corporation (NYSE: DHR) filed this Form 8-K on January 13, 2025, furnishing a preliminary update on its fourth quarter 2024 results ahead of CEO Rainer M. Blair's presentation at the J.P. Morgan Healthcare Conference on January 14, 2025. The company estimates Q4 2024 total (GAAP) revenue grew in the low-single-digit percent range year-over-year, while non-GAAP core revenue was expected to be essentially flat. Management said core revenue came in above its previously guided low-single-digit percent decline, with Bioprocessing performing in line with expectations, Diagnostics slightly above expectations (led by higher respiratory demand at Cepheid), and Life Sciences modestly better than anticipated, driven by instrumentation. The company reaffirmed that its Q4 adjusted operating profit margin is expected to be consistent with prior guidance, with better-than-expected operational performance offset by foreign exchange headwinds. The presentation also provided a portfolio overview: 2024E total revenue of roughly $24 billion across Diagnostics (~$9.8B), Life Sciences (~$7.3B), and Bioprocessing (~$6.8B), with about 80% recurring revenue and a stated long-term high-single-digit core revenue growth target for Bioprocessing and Life Sciences. Investors should note that these are estimates furnished rather than filed, and that the full Q4 and FY2024 earnings release is scheduled for January 29, 2025.

Jan 13, 2025 8-K

DANAHER CORP /DE/ 8-K Report, Executive Changes (Dec 11, 2024)

Danaher Corporation (DHR) announced on December 10, 2024, the retirement of Dr. Pardis C. Sabeti from its Board of Directors, effective the same date. This departure is attributed to Dr. Sabeti's existing professional commitments and is explicitly stated as not being the result of any disagreement with the company. Investors should note that this change on the Board does not appear to be linked to any operational or strategic issues within Danaher. The filing also includes the standard cover page interactive data file as an exhibit. For investors, the primary takeaway is the smooth transition regarding Dr. Sabeti's board seat, maintaining stability within the company's governance structure. No financial statements or material business updates were disclosed in this particular 8-K filing, suggesting it is primarily administrative in nature.

Dec 11, 2024 8-K

DANAHER CORP /DE/ 8-K Report, Financial Results (Oct 22, 2024)

Danaher reported third-quarter 2024 results for the period ended September 27, 2024, with GAAP net earnings from continuing operations of $818 million, or $1.12 per diluted share, versus $1.26 a year earlier. Non-GAAP adjusted diluted EPS from continuing operations was $1.71, compared with $1.72 in the prior-year quarter, a slight decline. Revenue rose 3.0% year-over-year to $5.8 billion, but this headline growth was driven by acquisitions (about 2.5 points, largely Abcam). Non-GAAP core revenue grew only 0.5%, with Diagnostics (+5.0%, supported by Cepheid molecular testing share gains) and Biotechnology flat, offset by a 2.0% decline in Life Sciences. Management highlighted positive momentum in bioprocessing. GAAP operating profit fell to $958 million from $1,185 million, largely due to a $222 million pretax impairment of a Life Sciences trade name and higher SG&A expenses, which rose to $2.06 billion from $1.73 billion. Interest income dropped sharply to $4 million from $79 million, reflecting lower cash balances after prior-year divestiture proceeds. Operating cash flow from continuing operations was $1.5 billion, and free cash flow was $1.2 billion, up about 12% year-over-year. Looking ahead, Danaher expects fourth-quarter 2024 and full-year 2024 non-GAAP core revenue to decline at a low-single-digit rate year-over-year, unchanged from prior guidance. The company is therefore not expecting a near-term acceleration in organic growth, and investors will likely focus on the pace of recovery in bioprocessing and diagnostics and the trajectory of COVID-19-related demand declines.

Oct 22, 2024 10-Q

DANAHER CORP /DE/ Quarterly Report for Q3 Ended Sep 27, 2024

Danaher's third-quarter 2024 10-Q shows a quarter where top-line growth was modest but profitability fell sharply, driven largely by a non-cash impairment. Q3 sales rose 3.0% to $5.80 billion, with core sales up only 0.5% and acquisitions adding 2.5%. Operating profit fell 19% to $958 million, and operating margin compressed 460 basis points to 16.5%. Diluted EPS from continuing operations was $1.12, down from $1.26. The margin decline was driven primarily by a $222 million pretax trade name impairment in the Life Sciences genomics consumables business, plus dilution from acquisitions and weaker Life Sciences core sales. For the nine months, sales declined 1.0% to $17.34 billion and core sales fell 2.0%, led by a roughly 8.5% core decline in Biotechnology as customers worked down inventory. Diagnostics was the bright spot, with core sales up 5.0% and operating margin up 410 basis points to 28.0%. Net earnings from continuing operations were $2.81 billion, down from $3.10 billion. Operating cash flow was $4.67 billion, and the company returned substantial capital, repurchasing about $5.2 billion of common stock and paying $573 million in dividends. The balance sheet remains substantial but is less liquid. Cash fell to $2.6 billion from $5.9 billion at year-end 2023, and total debt declined to $17.5 billion. Management expects the bioprocessing business to return to high-single-digit core growth in Q4 2024 while full-year bioprocessing core sales decline at a low-single-digit rate. The company also flagged softness in genomics and weaker demand from smaller biopharma customers as ongoing risks.

Oct 22, 2024 8-K

DANAHER CORP /DE/ 8-K Report, Financial Results (Jul 23, 2024)

Danaher Corporation (NYSE: DHR) reported second quarter 2024 results for the quarter ended June 28, 2024, with revenue of $5.7 billion, down 3.0% year-over-year (GAAP), and non-GAAP core revenue down 3.5%. GAAP net earnings were $907 million, or $1.22 per diluted share, versus $1.24 in the prior-year quarter from continuing operations. Non-GAAP adjusted diluted EPS was $1.72, compared with $1.73 a year earlier, a roughly flat result. Operating cash flow was $1.4 billion and non-GAAP free cash flow from continuing operations was $1.1 billion, down about 14.5% year-over-year, largely reflecting lower operating cash generation and higher capital spending relative to the prior year period. The quarter's segment picture was mixed. Biotechnology core sales fell 7.0% and Life Sciences core sales fell 5.5%, while Diagnostics grew 3.0%, supported by Cepheid, which management believes gained molecular testing share. Management highlighted sustained positive momentum in bioprocessing. Management reiterated its outlook for non-GAAP core revenue to decline at a low-single-digit rate in both the third quarter and full year 2024, which signals no near-term recovery in the top line. Investors will likely focus on whether the bioprocessing recovery and Diagnostics strength can offset weakness in Life Sciences and Biotechnology. The filing also shows a large financing outflow of $5.7 billion in the quarter, which is well above the operating cash flow for the period. Because the filing does not explain this outflow, investors should review the Form 10-Q for details on debt repayment or other financing activity. Net earnings were pressured by higher amortization of acquisition-related intangibles ($402 million pretax in the quarter), and interest income declined year-over-year, from $59 million to $39 million.

Jul 23, 2024 10-Q

DANAHER CORP /DE/ Quarterly Report for Q2 Ended Jun 28, 2024

Danaher's Q2 2024 10-Q shows a quarter of weaker organic performance and a heavy capital return. Sales fell 3.0% year over year to $5.74 billion, with core sales down 3.5%. Biotechnology was the main drag, with core sales down 7.0% in the quarter and 12.0% year to date, driven by customers destocking bioprocessing inventory. Diagnostics grew core sales 3.0%, and Life Sciences declined 5.5%. Diluted EPS from continuing operations was $1.22, versus $1.24 a year earlier, as higher SG&A (including Abcam-related amortization) and lower interest income offset a lower tax rate and improved gross margin. Balance sheet and capital allocation changed sharply. Cash fell from $5.9 billion at year-end 2023 to $2.4 billion, and total debt declined to $17.0 billion from $18.4 billion after the April repayment of the EUR 900 million 2024 Euronotes. In the quarter the company repurchased about 17.4 million shares for roughly $4.6 billion, and the board authorized an additional 20 million shares in July 2024. Goodwill and intangibles fell primarily due to foreign currency translation, and accumulated other comprehensive loss widened to $2.6 billion. Management expects bioprocessing core revenue to decline for full-year 2024 with gradual sequential improvement, and guided the remaining-2024 effective tax rate to about 17.5%. Investors will focus on whether Biotechnology stabilizes, whether Diagnostics growth continues, and how the much smaller cash position affects future M&A capacity.

Jul 23, 2024 8-K

DANAHER CORP /DE/ 8-K Report, Executive Changes (Jun 20, 2024)

Danaher Corporation (DHR) has filed an 8-K report to disclose the departure of Joakim Weidemanis from his role as Executive Vice President, effective July 1, 2024. Mr. Weidemanis will continue to be employed by Danaher through September 30, 2024, to provide transition services, ensuring a smooth handover of his responsibilities. This filing outlines the terms of his transition, including continued salary and a pro-rated incentive compensation award for 2024, contingent on certain performance factors and a release of claims. While the departure of a key executive can sometimes raise investor concerns, Danaher's proactive approach in securing transition services and detailing the compensation terms aims to mitigate disruption. Investors should monitor the company's performance and strategic execution in the coming quarters, particularly in areas previously overseen by Mr. Weidemanis, to assess any potential impact on the business. The filing also includes the Transition Agreement as an exhibit, providing transparency on the executive's departure terms.

Jun 20, 2024 8-K

DANAHER CORP /DE/ 8-K Report, Shareholder Vote Results (May 9, 2024)

Danaher Corporation (DHR) filed an 8-K on May 8, 2024, detailing the results of its annual shareholder meeting held on May 7, 2024. The primary focus of this filing is the voting outcomes on several key proposals. Notably, all thirteen director nominees were elected, and shareholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the upcoming fiscal year. The advisory vote on executive compensation also received shareholder approval.

May 9, 2024 8-K

DANAHER CORP /DE/ 8-K Report, Financial Results (Apr 23, 2024)

Danaher Corporation (NYSE: DHR) reported first quarter 2024 results for the quarter ended March 29, 2024, with revenue of $5.8 billion, down 2.5% year-over-year from $5.9 billion, and non-GAAP core revenue down 4.0%. GAAP net earnings were $1.1 billion, or $1.45 per diluted share, compared with $1.65 per diluted share from continuing operations a year earlier. Non-GAAP adjusted diluted EPS was $1.92, down from $2.05 in the prior-year period. The decline in GAAP earnings was driven by lower gross profit, higher SG&A, and a lower operating margin, partly offset by lower income taxes. Note that the prior-year GAAP net earnings included $210 million from discontinued operations, so the year-over-year comparison of total net earnings is not like-for-like. By segment, Biotechnology core sales fell 17.0%, Life Sciences core sales declined 3.0%, and Diagnostics core sales grew 7.5%. Management highlighted improving order trends in bioprocessing and continued share gains in molecular diagnostics at Cepheid. Operating cash flow was $1.7 billion and non-GAAP free cash flow was $1.4 billion, both modestly lower than the prior year. Acquisitions, notably Abcam, contributed roughly 2 percentage points to reported revenue growth, and currency added about 0.5 points. Guidance was mixed relative to the quarter. For the second quarter of 2024, management expects non-GAAP core revenue to decline by a mid-single-digit percentage year-over-year, and for full year 2024 it continues to expect a low-single-digit core revenue decline. Investors will watch whether bioprocessing recovery and Cepheid strength can offset weakness in Biotechnology and Life Sciences as the year progresses.

Apr 23, 2024 10-Q

DANAHER CORP /DE/ Quarterly Report for Q1 Ended Mar 29, 2024

Danaher's first quarter 2024 results (quarter ended March 29, 2024) show a clear top-line and margin slowdown, concentrated in its Biotechnology segment. Total sales fell 2.5% year-over-year to $5.80 billion, while core sales (excluding acquisitions and currency) declined 4.0%. Diluted EPS from continuing operations was $1.45, down from $1.65 a year earlier, and operating margin compressed 290 basis points to 22.6%. Management attributes the weakness mainly to a sharp decline in Biotechnology sales (down 18.0% reported, 17.0% core), driven by bioprocessing customers cutting inventory and emerging biotech customers conserving capital amid a tighter funding environment. Management expects bioprocessing core revenue to decline for full-year 2024, with gradual improvement through the year. Diagnostics was the bright spot, with sales up 6.5% and operating margin up 430 basis points to 32.8%, led by molecular diagnostics. The balance sheet and cash position look solid, though with some caveats. Cash and equivalents rose to $7.0 billion from $5.9 billion, and operating cash flow from continuing operations was $1.7 billion. However, the increase in cash was helped by a sizable foreign currency translation loss of $948 million that hit comprehensive income, which fell to $92 million from $1.56 billion. Total debt was $18.2 billion, and the company repaid a €900 million Euronote on April 2, 2024 using cash distributed by Veralto before the separation. Goodwill and intangibles remain large, at roughly $60.7 billion combined, and the company reported no impairment triggers. Quarterly results are also not directly comparable with the prior year, since they exclude Veralto (a discontinued operation) and include the Abcam acquisition.

Apr 23, 2024 10-K

DANAHER CORP /DE/ Annual Report, Year Ended Dec 31, 2023

Danaher Corporation (DHR) reported a decrease in total sales and net earnings for the fiscal year ended December 31, 2023, compared to the previous year. This decline was primarily driven by a significant reduction in demand for COVID-19 related products and a general slowdown in certain end markets. The company's core sales also saw a notable decrease. Despite the overall revenue decline, Danaher continued to execute its strategic priorities, including the significant acquisition of Abcam plc for $5.6 billion, strengthening its Life Sciences segment. The company also completed the separation of its former Environmental & Applied Solutions business into Veralto Corporation. Danaher's diversified business segments—Biotechnology, Life Sciences, and Diagnostics—face varying market dynamics, with Biotechnology experiencing the most pronounced sales decrease due to the normalization of COVID-19 related demand. The company remains focused on innovation, operational efficiency through its Danaher Business System (DBS), and strategic capital allocation for long-term shareholder value creation.

Feb 21, 2024 8-K

DANAHER CORP /DE/ 8-K Report, Executive Changes (Feb 14, 2024)

Danaher Corporation (DHR) filed an 8-K on February 14, 2024, to announce a significant change in its Board of Directors. Walter G. Lohr, Jr., a long-standing member of the Board, has decided not to seek reelection at the upcoming annual meeting of shareholders on May 7, 2024. He will officially retire from the Board at that time. Importantly, the filing clarifies that Mr. Lohr's decision is voluntary and not due to any disputes or disagreements with the company regarding its operations, policies, or practices.

Feb 14, 2024 8-K

DANAHER CORP /DE/ 8-K Report, Financial Results (Jan 30, 2024)

Danaher's (DHR) Q4 and full-year 2023 results, furnished under Item 2.02, show a year of sharp top-line contraction as COVID-19 demand unwound, with partial offsets from the Abcam acquisition and the Veralto spin-off. Fourth-quarter revenue fell 10.0% year-over-year to $6.4 billion, with non-GAAP core revenue down 11.5% (including a 4.5% base business decline). Full-year revenue declined 10.5% to $23.9 billion, with core revenue down 10.0%. GAAP diluted EPS from continuing operations was $1.50 in Q4 and $5.65 for the year, while non-GAAP adjusted diluted EPS was $2.09 and $7.58, respectively. Adjusted EPS was down from $2.54 and $9.71 in the prior-year periods. Operating margin compressed meaningfully, with GAAP operating margin at 20.9% in Q4 versus 28.0% a year earlier, and 21.8% for the full year versus 28.3%. Cash generation remained solid but weaker. Operating cash flow from continuing operations was $6.5 billion for the year (down about 15%), and free cash flow was $5.1 billion (down about 21.5%). Q4 free cash flow fell about 38% to $1.2 billion. The balance sheet expanded substantially, with goodwill rising to $41.6 billion from $37.3 billion and total debt-related liabilities remaining large, as the company completed the Abcam acquisition, which cost roughly $5.6 billion in cash paid for acquisitions in 2023. Management characterized 2023 as transformational following the Veralto spin-off, positioning Danaher as a more focused Life Sciences and Diagnostics company. Looking ahead, management guided non-GAAP core revenue to decline high-single digits year-over-year in Q1 2024 and low-single digits for full-year 2024. The company will stop guiding to and reporting base business core revenue, reflecting its view that the pandemic has transitioned to an endemic state. For investors, the key takeaways are the magnitude of the COVID-related revenue unwind, the margin and cash flow pressure, and the near-term guidance, which signals continued softness before any recovery, against the backdrop of a larger, Abcam-enhanced proteomics portfolio.

Jan 30, 2024 8-K

DANAHER CORP /DE/ 8-K Report, Financial Results (Jan 8, 2024)

Danaher Corporation (NYSE: DHR) furnished an 8-K on January 8, 2024, ahead of CEO Rainer M. Blair's presentation at the J.P. Morgan Healthcare Conference on January 9, 2024. The company provided a preliminary read on fourth-quarter 2023 performance: total revenue is estimated to decline in the low-double-digit percent range year over year. Non-GAAP core revenue is expected to fall in the low-double-digit range, which is better than the previously guided high-teens percent decline. Base business core revenue is expected to decline in the mid-single-digit range, in line with prior guidance. The decline is driven largely by the post-pandemic normalization of COVID-19 testing, vaccine, and therapeutics demand, partly offset by currency and acquisitions. Management indicated that Q4 results were better than anticipated in a challenging operating environment. Life Sciences and Biotechnology both modestly exceeded expectations, and respiratory revenue at Cepheid topped $600 million, above expectations. Management expects Q4 2023 adjusted operating profit margin to be in line with or above the prior guidance of roughly 28%. The Abcam acquisition closed in December 2023, ahead of the company's initial timeline. The presentation frames Danaher's portfolio transformation since 2018, when it had roughly $24 billion in revenue, including exits of Dental and Environmental & Applied Solutions and the divestiture of Cytiva. The company now targets roughly $20 billion in 2023E revenue, with a stronger mix toward Diagnostics and Life Sciences, and about 80% recurring revenue. Investors should note that the company did not provide full-year 2024 guidance in this filing, and that the figures are preliminary estimates subject to the upcoming Q4 earnings call on January 30, 2024.

Jan 8, 2024 10-Q

DANAHER CORP /DE/ Quarterly Report for Q3 Ended Sep 29, 2023

Danaher's Q3 2023 10-Q shows a sharp top-line and profit decline driven by COVID-related demand normalization and softer bioprocessing and diagnostics demand. Third-quarter sales fell 10.5% to $6.87 billion (core sales down 11.5%), and nine-month sales fell 8.0% to $21.2 billion (core down 7.5%). Operating margin compressed to 20.9% in the quarter from 26.3% a year earlier, and diluted EPS fell to $1.51 from $2.10. Nine-month diluted EPS was $4.94 versus $6.67. Management attributes the weakness mainly to lower COVID-19 testing and therapeutics demand, reduced bioprocessing inventory at customers, and tighter funding for emerging biotech companies, with China Biotechnology core sales declining sharply. Balance sheet and capital structure changed materially in the quarter. Cash rose to $12.3 billion from $6.0 billion at year-end 2022, largely because Veralto, the spun-off Environmental & Applied Solutions business, issued about $2.6 billion of debt and distributed the proceeds to Danaher before the September 30 separation. Total debt rose to about $22.1 billion, including $2.6 billion of Veralto bonds that will leave the group in the fourth quarter. Operating cash flow was $5.5 billion for the nine months, down 7%. The filing also discloses a pending $5.7 billion cash acquisition of Abcam, expected to be funded with cash on hand and commercial paper, which will add to leverage and integration risk. Investors should weigh the cyclical trough in Biotechnology and Diagnostics against a still-strong liquidity position and a balance sheet that will be restated once Veralto is reported as a discontinued operation in Q4 2023. The company guided to a full-year 2023 effective tax rate near 18.5%, declared a $0.27 quarterly dividend, and made no share repurchases during the quarter.

Oct 24, 2023 8-K

DANAHER CORP /DE/ 8-K Report, Financial Results (Oct 24, 2023)

Danaher Corporation (NYSE: DHR) reported third quarter 2023 results for the period ended September 29, 2023, showing a challenging top line and a better-than-expected earnings and cash flow profile. GAAP sales fell 10.5% year-over-year to $6.9 billion, and non-GAAP core revenue declined 11.5%, including a 3.0% decline in the base business (which excludes COVID-19 testing, vaccines and therapeutics). GAAP net earnings were $1.1 billion, or $1.51 per diluted share, versus $2.10 a year earlier, while non-GAAP adjusted diluted EPS was $2.02 versus $2.56. Operating cash flow was $1.7 billion and free cash flow was $1.3 billion, down about 24.5% year-over-year. Management attributed the quarter's upside to Biotechnology performing as anticipated and higher respiratory testing revenue, partly offset by softer-than-expected Life Sciences demand. The most significant structural event is the September 30, 2023 spin-off of Veralto Corporation (the former Environmental & Applied Solutions business) to Danaher shareholders. Results in this release still include Veralto, but guidance covers only continuing operations, and future filings will present Veralto as a discontinued operation. Management guided fourth-quarter base business core revenue down mid-single digits and full-year 2023 base business core revenue down slightly, with total core revenue expected to fall in the high-teens in Q4 and low-double digits for the full year, largely reflecting the decline in COVID-19 related demand. Investors should therefore focus on the continuing-operations base business trend and the post-spin earnings power rather than the reported headline decline. This 8-K furnishes the earnings release under Item 2.02 and is not deemed filed for Exchange Act Section 18 purposes. The release also notes the pending acquisition of Abcam plc as a forward-looking factor. Separation costs of $0.14 per share for the nine months and impairment charges weighed on GAAP results, which the company excluded from its non-GAAP metrics.

Oct 24, 2023 8-K

DANAHER CORP /DE/ 8-K Report, Material Agreement (Oct 2, 2023)

On October 2, 2023, Danaher (NYSE: DHR) disclosed the completion of its spin-off of Veralto Corporation (NYSE: VLTO), which holds Danaher's former Environmental & Applied Solutions segment (Water Quality and Product Quality & Innovation businesses). The separation was effected on September 30, 2023, when Danaher stockholders received one Veralto share for every three Danaher shares held at the September 13, 2023 record date. About 246 million Veralto shares were distributed, and regular-way trading of VLTO began October 2, 2023. The distribution is intended to be tax-free to U.S. stockholders for federal income tax purposes, except for cash received in lieu of fractional shares. Danaher's stock is expected to trade ex-distribution, so its price should mechanically fall by the value of the spun-off Veralto stake. The filing also details a set of definitive agreements dated September 29, 2023 governing the relationship between the two companies, including a Separation and Distribution Agreement, Employee Matters, Tax Matters, Transition Services, Intellectual Property Matters, DBS License, and a Framework Agreement covering particle counting products. Veralto is paying Danaher a cash distribution of approximately $2.7 billion, funded by about $2.6 billion of unsecured notes plus roughly $100 million of cash on hand, and is putting in place a $1.5 billion revolving credit facility. Pro forma figures from the information statement show roughly $4.9 billion in 2022 sales, about 23% operating margin, and approximately $2.6 billion of debt at separation. Jennifer Honeycutt, an executive officer at Danaher, resigned from that role effective at the distribution because she is becoming CEO of Veralto. For investors, the key takeaways are the mechanical share-price adjustment at Danaher, the new standalone Veralto equity with its own leverage and capital allocation priorities, and the dependence of Veralto on Danaher through transition services, IP licenses, and tax-related indemnities. Tax-matters risk is significant: if the IRS private letter ruling or the tax opinion proves incorrect, both companies could face material tax liabilities. Investors should also note that Veralto is a newly public company with no operating history as a standalone entity, so its historical and pro forma financials may not be indicative of future results.

Oct 2, 2023 8-K

DANAHER CORP /DE/ 8-K Report, Material Agreement (Sep 19, 2023)

Danaher Corporation (DHR) has announced a significant financing transaction through its wholly-owned subsidiary, Veralto Corporation. Veralto has issued a substantial amount of senior notes in both U.S. dollar and Euro denominations, totaling $2.1 billion and €500 million respectively. These notes are intended to fund the upcoming separation of Veralto from Danaher, a spin-off event anticipated by investors. Danaher has provided full and unconditional guarantees for these notes, which will be released upon the completion of the Veralto separation.

Sep 19, 2023 8-K

DANAHER CORP /DE/ 8-K Report, Corporate Update (Sep 12, 2023)

This 8-K filing from Danaher Corporation (DHR) details significant debt offerings by its subsidiary, Veralto Corporation, in preparation for Veralto's planned separation from Danaher. Veralto has agreed to issue a substantial amount of senior notes denominated in both USD and EUR, totaling approximately $2.1 billion and €500 million respectively, with various maturity dates and interest rates. These offerings are crucial for financing the separation and providing Veralto with its own capital structure as it prepares to operate as an independent entity. Danaher will guarantee these notes until the separation is complete, after which Veralto will be solely responsible. The proceeds from these offerings will be used by Veralto to make payments to Danaher as partial consideration for the assets contributed during the separation, as well as to cover associated fees and expenses. Investors should note that these notes are being sold in private placements to qualified institutional buyers and non-U.S. persons, and Veralto intends to register similar notes later to facilitate resales.

Sep 12, 2023 8-K

DANAHER CORP /DE/ 8-K Report, Material Agreement (Aug 31, 2023)

Danaher Corporation (DHR) has filed an 8-K report to disclose the entry into a material definitive agreement concerning a new credit facility. This report details a $1.5 billion unsecured five-year credit facility secured by its wholly-owned subsidiary, Veralto Corporation. The facility, effective August 31, 2023, with a maturity date of August 31, 2028, provides Veralto with significant liquidity and flexibility. The credit facility includes provisions for an extension option and an expansion option of up to $500 million, indicating potential future financing needs or growth opportunities. The terms of the facility establish interest rate mechanisms tied to Veralto's credit rating and include a facility fee. Crucially, Veralto is required to maintain a specific Consolidated Net Leverage Ratio, with a temporary increase allowed following significant acquisitions. This facility is intended to support Veralto's commercial paper program and general corporate purposes, and borrowings are contingent upon the completion of the previously announced separation of Danaher's Environmental & Applied Solutions business into Veralto.

Aug 31, 2023 8-K

DANAHER CORP /DE/ 8-K Report, Temporary Suspension of Trading Under Employee Benefit Plans (Aug 31, 2023)

Danaher Corporation's Form 8-K, filed August 31, 2023, is an administrative disclosure about a temporary trading blackout tied to the spin-off of Veralto Corporation. Danaher expects to distribute all of its Veralto common stock to stockholders on September 30, 2023, with fractional shares sold in the market and the proceeds paid out. The separation changes the Danaher Stock Fund in five employee benefit plans, so participants and beneficiaries will temporarily be unable to transfer money into or out of that fund. The blackout is expected to run from September 29, 2023 at 4:00 p.m. ET through October 5, 2023 at 4:00 p.m. ET. Because the restriction affects more than half of plan participants for more than three consecutive business days, Sarbanes-Oxley Section 306(a) and Regulation BTR apply. Danaher's directors and Section 16 officers are therefore barred, subject to limited exemptions, from buying, selling, or transferring Danaher common stock or related derivatives acquired through their Danaher service. Danaher will update the blackout dates if the spin-off date changes. For investors, the filing carries no direct financial results or guidance. Its main significance is the confirmed timetable for the Veralto separation and the roughly one-week window in which insider trading is restricted, which is useful for tracking insider activity around the spin-off.

Aug 31, 2023